Flamingo Therapeutics 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IONIS-AR-2.5Rx / Flamingo Therapeutics
ChiCTR2100044174: A Phase IIa Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ISIS 560131 in Patients with Metastatic Castration-Resistant Prostate Cancer with Positive Androgen Receptor Splicing Variant 7 (AR-V7)

Recruiting
2
36
 
Drug treatment (IV) ;Drug treatment (IV)
West China Hospital of Sichuan University; West China Hospital of Sichuan University, provided by enterprises
AR-V7-positive metastatic castration-resistant prostate cancer (mCRPC)
 
 
danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
NCI-2018-01296, NCT02983578: Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Active, not recruiting
2
39
US
Danvatirsen, AZD9150, ISIS 481464, ISIS-STAT3rx, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
M.D. Anderson Cancer Center, National Cancer Institute (NCI), AstraZeneca
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Mismatch Repair Deficiency, Refractory Colorectal Carcinoma, Refractory Lung Carcinoma, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
08/25
08/25
HUDSON, NCT03334617 / 2017-002208-28: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Jan 2024 - Dec 2024: Data from HUDSON trial for NSCLC
Active, not recruiting
2
527
Europe, Canada, US, RoW
Durvalumab, AZD9150, AZD6738, Vistusertib, Olaparib, Oleclumab, trastuzumab deruxtecan, cediranib, AZD6738 (ceralasertib), AZD6738 (ceralasertib) (240 mg or 160 mg), AZD6738 (ceralasertib) 7 days monotherapy
AstraZeneca
Non-Small Cell Lung Cancer
09/24
09/26
PEMDA-HN, NCT05814666: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Recruiting
2
81
Europe, US, RoW
Danvatirsen, ISIS 481464, AZD9150, Pembrolizumab, Keytruda
Flamingo Therapeutics NV
HNSCC
05/25
05/26
NCT02499328 / 2015-002525-19: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Checkmark In combination with tremelimumab for metastatic SCCHN
Jan 2019 - Jan 2019: In combination with tremelimumab for metastatic SCCHN
Checkmark In combination with danvatirsen for metastatic squamous cell carcinoma of the head and neck
Oct 2018 - Oct 2018: In combination with danvatirsen for metastatic squamous cell carcinoma of the head and neck
Active, not recruiting
1/2
340
Europe, US
AZD9150, MEDI4736, AZD5069, tremelimumab (treme)
AstraZeneca, MedImmune LLC
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
02/20
08/25
NCT03421353: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Hourglass Jan 2019 - Dec 2020 : Data from P1b/2 trial of Imfinzi in combination with AZD9150 for NSCLC
Completed
1
76
US
AZD9150, Durvalumab, MEDI4736, Cisplatin, 5-Flourouracil, 5-FU, Carboplatin, Gemcitabine, Nab-paclitaxel
AstraZeneca
Advanced Solid Tumours
01/20
03/24
BISCAY, NCT02546661 / 2015-002228-25: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Hourglass Mar 2020 - Mar 2020 : Completion of P1 trial in 2nd+ line muscle invasive metastatic bladder cancer
Checkmark From BISCAY trial for muscle-invasive bladder cancer
Sep 2019 - Sep 2019: From BISCAY trial for muscle-invasive bladder cancer
Active, not recruiting
1
117
Europe, Canada, US
AZD4547, MEDI4736, Durvalumab, Olaparib, Lynparza, AZD1775, Vistusertib, AZD9150, Selumetinib
AstraZeneca
Muscle Invasive Bladder Cancer
03/20
01/26
MAGELLAN, NCT03819465 / 2018-001748-74: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Jan 2024 - Dec 2024: Data from MAGELLAN trial for 1L NSCLC
Active, not recruiting
1
175
Europe, US, RoW
Durvalumab, MEDI4736, Danvatirsen, AZD9150, Oleclumab, MEDI9447, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
05/23
03/26
NCT05986240: Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Recruiting
1
24
US
Danvatirsen, AZD9150, Danvatirsen + Venetoclax, Venclexta
Montefiore Medical Center, M.D. Anderson Cancer Center, Flamingo Therapeutics NV
AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
10/25
07/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IONIS-AR-2.5Rx / Flamingo Therapeutics
ChiCTR2100044174: A Phase IIa Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ISIS 560131 in Patients with Metastatic Castration-Resistant Prostate Cancer with Positive Androgen Receptor Splicing Variant 7 (AR-V7)

Recruiting
2
36
 
Drug treatment (IV) ;Drug treatment (IV)
West China Hospital of Sichuan University; West China Hospital of Sichuan University, provided by enterprises
AR-V7-positive metastatic castration-resistant prostate cancer (mCRPC)
 
 
danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
NCI-2018-01296, NCT02983578: Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Active, not recruiting
2
39
US
Danvatirsen, AZD9150, ISIS 481464, ISIS-STAT3rx, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
M.D. Anderson Cancer Center, National Cancer Institute (NCI), AstraZeneca
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Mismatch Repair Deficiency, Refractory Colorectal Carcinoma, Refractory Lung Carcinoma, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
08/25
08/25
HUDSON, NCT03334617 / 2017-002208-28: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Jan 2024 - Dec 2024: Data from HUDSON trial for NSCLC
Active, not recruiting
2
527
Europe, Canada, US, RoW
Durvalumab, AZD9150, AZD6738, Vistusertib, Olaparib, Oleclumab, trastuzumab deruxtecan, cediranib, AZD6738 (ceralasertib), AZD6738 (ceralasertib) (240 mg or 160 mg), AZD6738 (ceralasertib) 7 days monotherapy
AstraZeneca
Non-Small Cell Lung Cancer
09/24
09/26
PEMDA-HN, NCT05814666: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Recruiting
2
81
Europe, US, RoW
Danvatirsen, ISIS 481464, AZD9150, Pembrolizumab, Keytruda
Flamingo Therapeutics NV
HNSCC
05/25
05/26
NCT02499328 / 2015-002525-19: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Checkmark In combination with tremelimumab for metastatic SCCHN
Jan 2019 - Jan 2019: In combination with tremelimumab for metastatic SCCHN
Checkmark In combination with danvatirsen for metastatic squamous cell carcinoma of the head and neck
Oct 2018 - Oct 2018: In combination with danvatirsen for metastatic squamous cell carcinoma of the head and neck
Active, not recruiting
1/2
340
Europe, US
AZD9150, MEDI4736, AZD5069, tremelimumab (treme)
AstraZeneca, MedImmune LLC
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
02/20
08/25
NCT03421353: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Hourglass Jan 2019 - Dec 2020 : Data from P1b/2 trial of Imfinzi in combination with AZD9150 for NSCLC
Completed
1
76
US
AZD9150, Durvalumab, MEDI4736, Cisplatin, 5-Flourouracil, 5-FU, Carboplatin, Gemcitabine, Nab-paclitaxel
AstraZeneca
Advanced Solid Tumours
01/20
03/24
BISCAY, NCT02546661 / 2015-002228-25: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Hourglass Mar 2020 - Mar 2020 : Completion of P1 trial in 2nd+ line muscle invasive metastatic bladder cancer
Checkmark From BISCAY trial for muscle-invasive bladder cancer
Sep 2019 - Sep 2019: From BISCAY trial for muscle-invasive bladder cancer
Active, not recruiting
1
117
Europe, Canada, US
AZD4547, MEDI4736, Durvalumab, Olaparib, Lynparza, AZD1775, Vistusertib, AZD9150, Selumetinib
AstraZeneca
Muscle Invasive Bladder Cancer
03/20
01/26
MAGELLAN, NCT03819465 / 2018-001748-74: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Jan 2024 - Dec 2024: Data from MAGELLAN trial for 1L NSCLC
Active, not recruiting
1
175
Europe, US, RoW
Durvalumab, MEDI4736, Danvatirsen, AZD9150, Oleclumab, MEDI9447, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
05/23
03/26
NCT05986240: Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Recruiting
1
24
US
Danvatirsen, AZD9150, Danvatirsen + Venetoclax, Venclexta
Montefiore Medical Center, M.D. Anderson Cancer Center, Flamingo Therapeutics NV
AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
10/25
07/28

Download Options